The chemo-free concept represents a new direction for managing adult patients with Ph-positive acute lymphoblastic leukemia (Ph + ALL). The tyrosine kinase inhibitors (TKIs), blinatumomab and venetoclax serve as the backbone of chemo-free regimens; several prospective studies involving these drugs have demonstrated high remission rates and promising, albeit short, survival outcomes. This review summarizes the latest updates on chemo-free regimens in the treatment of adult patients with Ph + ALL, presented at the 2023 ASH annual meeting.

中文翻译：

---

Ph 阳性急性淋巴细胞白血病成人患者的无化疗治疗：2023 年 ASH 年会的最新更新

免化疗概念代表了治疗 Ph 阳性急性淋巴细胞白血病 (Ph + ALL) 成年患者的新方向。酪氨酸激酶抑制剂 (TKI)、blinatumomab 和 Venetoclax 是无化疗方案的支柱；涉及这些药物的几项前瞻性研究表明，缓解率很高，并且有希望（尽管短暂）的生存结果。本综述总结了 2023 年 ASH 年会上提出的治疗 Ph + ALL 成人患者的无化疗方案的最新进展。